'Trump To Sign Order To Encourage Domestic Drug Manufacturing' - Washington Post

Benzinga23:04 ET

Citi maintains INNOVENT BIO's "Outperform the Industry" rating and raises the Target Price to 66 Hong Kong dollars.

CITIC published a Research Report stating that it maintains INNOVENT BIO (01801) Net income forecasts for 2025/2026 at 0.472 billion yuan/1.298 billion yuan unchanged. The firm maintains an outperform rating in the Industry. Considering the maturity of the next-generation flagship product IBI363 PoC data and the progress of the ADC pipeline, it is expected to unlock a broader Global commercialization space. Based on the DCF model, the firm raised the Target Price by 12.2% to 66 Hong Kong dollars, which has an upside potential of 20.2% compared to the current stock price. Event: On May 1, the company announced that product revenue for the first quarter of 2025 exceeded 2.4 billion yuan, maintaining over 40% year-on-year growth.

Sina Hong Kong Stocks22:37 ET

Eli Lilly and Co To Go Ex-Dividend On May 16th, 2025 With 1.5 USD Dividend Per Share

Moomoo News19:35 ET

Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $944

Moomoo News19:31 ET · Ratings

Fund Update: National Mutual Insurance Federation of Agricultural Cooperatives Added 15,200 Shares of ELI LILLY ($LLY) to Their Portfolio

Quiver Quantitative14:16 ET

Express News | Eli Lilly and Co - Declares Q2 2025 Dividend of $1.50 per Share

Reuters12:47 ET